Publications

Health policy (Amsterdam, Netherlands)

Coverage with evidence development programs: a scoping review on characteristics and patient access.

01-09-2026

The Lancet. Oncology

Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis.

08-07-2026

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Human epididymis protein 4 and risk of malignancy index as risk assessment tools in the decision for referral to an oncology center in patients with an ovarian mass: a cost-effectiveness analysis from a Dutch health care perspective.

01-07-2026

The Lancet. Oncology

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.

01-07-2026

The European journal of health economics : HEPAC : health economics in prevention and care

A comparative analysis of managed entry agreements in Europe: trends, reporting practices, and financial outcomes.

29-06-2026

International journal of cancer

Toward a validated European instrument to measure the socioeconomic impact of cancer.

15-06-2026

BMC cancer

Hepatic arterial infusion pump chemotherapy combined with systemic therapy versus systemic therapy alone as induction treatment for initially unresectable colorectal liver metastases: a study protocol of the randomised controlled trial - PUMP-IT RCT.

16-05-2026

Frontiers in pharmacology

Price transparency of cancer medicines: a crucial step towards informed pricing negotiations in the European region.

25-03-2026

Key Publication

Public health genomics

A Value-Based Evaluation Framework for Guiding the Adoption and Scale-Up of Cancer Genomics Interventions.

02-03-2026

BMJ open

Hospital-based real-world evidence in health technology assessment: insights from a scoping review of European, Australian and North American guidance and expert interviews.

31-12-2025

Key Publication

JCO oncology practice

Budget Impact Analysis of Hyperthermic Intraperitoneal Chemotherapy With Interval Cytoreductive Surgery in Ovarian Cancer.

19-12-2025

Nature medicine

Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial.

01-12-2025

Key Publication

JAMA network open

Economic Evaluation of Comprehensive Genomic Profiling in an Advanced Solid Cancer Population.

01-12-2025

Key Publication

Annals of oncology : official journal of the European Society for Medical Oncology

Health-related quality of life of patients with metastatic melanoma treated with tumor-infiltrating lymphocytes compared with ipilimumab in a randomized phase III trial.

01-10-2025

Key Publication

International journal of cancer

Socioeconomic impact among and socioeconomic support services for adolescents and young adults with cancer: A European perspective.

01-10-2025

Clinical drug investigation

Cost-Effectiveness of Pembrolizumab Monotherapy for High Programmed Death Ligand 1 Advanced or Metastatic Non-small Cell Lung Cancer Depends on Long-Term Survivors.

01-08-2025

ESMO open

Financial toxicity and socioeconomic impact of cancer in Europe.

01-06-2025

Key Publication

PharmacoEconomics - open

Very Early Health Technology Assessment for Potential Predictive Biomarkers in the Treatment of Advanced Non-Small Cell Lung Cancer.

01-05-2025

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Early Cost-Effectiveness Analysis of Using Whole-Genome Sequencing for Patients With Castration-Resistant Prostate Cancer.

01-05-2025

PharmacoEconomics

Towards Recommendations for Cost-Effectiveness Analysis of Predictive, Prognostic, and Serial Biomarker Tests in Oncology.

01-05-2025

The Lancet. Oncology

Defining the role of pragmatic clinical trials in cancer clinical research: outcomes of a collaborative workshop hosted by the European Organisation for Research and Treatment of Cancer.

01-05-2025

Journal of cancer survivorship : research and practice

"One more chance to survive": the experiences of patients with advanced melanoma and their partners with tumor-infiltrating lymphocyte therapy-a qualitative study and recommendations for future care.

01-02-2025

Future oncology (London, England)

An early economic evaluation of active surveillance for low-risk ductal carcinoma in situ.

01-12-2024

BMC cancer

Relevant factors for policy concerning comprehensive genomic profiling in oncology: stakeholder perspectives.

22-11-2024

Molecular oncology

A scenario-drafting study to explore potential future implementation pathways of circulating tumor DNA testing in oncology.

01-11-2024

Breast (Edinburgh, Scotland)

DCIS knowledge of women choosing between active surveillance and surgery for low-risk DCIS.

01-10-2024

Critical reviews in oncology/hematology

Factors for a broad technology assessment of comprehensive genomic profiling in advanced cancer, a systematic review.

01-10-2024

Acta oncologica (Stockholm, Sweden)

High-dose chemotherapy for patients with stage III breast cancer with homologous recombination deficiency: a discrete choice experiment among healthcare providers.

10-09-2024

Therapeutic advances in medical oncology

Early evaluation of the effectiveness and cost-effectiveness of ctDNA-guided selection for adjuvant chemotherapy in stage II colon cancer.

23-08-2024

Gynecologic oncology

Preferences and considerations for interval cytoreductive surgery in advanced ovarian cancer: The patient's perspective.

01-08-2024

European journal of cancer (Oxford, England : 1990)

EBCC-14 manifesto: Addressing disparities in access to innovation for patients with metastatic breast cancer across Europe.

01-08-2024

Scientific reports

Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.

16-05-2024

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery

Organization of head and neck cancer rehabilitation care: a national survey among healthcare professionals in Dutch head and neck cancer centers.

01-05-2024

JMIR research protocols

Effectiveness and Cost-Effectiveness of Survivorship Care for Survivors of Hodgkin Lymphoma (INSIGHT Study): Protocol for a Multicenter Retrospective Cohort Study With a Quasi-Experimental Design.

18-04-2024

The Lancet. Oncology

The socioeconomic impact of cancer on patients and their relatives: Organisation of European Cancer Institutes task force consensus recommendations on conceptual framework, taxonomy, and research directions.

01-04-2024

Journal for immunotherapy of cancer

Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial.

26-03-2024

International journal of cancer

Differences in time to patient access to innovative cancer medicines in six European countries.

01-03-2024

PharmacoEconomics - open

Early Cost-Effectiveness Analysis of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer Patients with Limited Peritoneal Carcinomatosis.

01-01-2024

Gynecologic oncology reports

Health state utility and health-related quality of life measures in patients with advanced ovarian cancer.

01-12-2023

BMC cancer

Personalized surveillance and aftercare for non-metastasized breast cancer: the NABOR study protocol of a multiple interrupted time series design.

14-11-2023

European journal of cancer (Oxford, England : 1990)

Active surveillance versus treatment in low-risk DCIS: Women's preferences in the LORD-trial.

01-10-2023

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation

Health-state utilities in long-term advanced melanoma survivors comparable with the general population.

01-09-2023

Drug discovery today

Targeted combination therapies in oncology: Challenging regulatory frameworks designed for monotherapies in Europe.

01-08-2023

European journal of cancer (Oxford, England : 1990)

Duty to recontact in genomic cancer care: A tool helping to assess the professional's responsibility.

01-06-2023

Radiology

Surveillance Imaging after Primary Diagnosis of Ductal Carcinoma in Situ.

01-04-2023

Frontiers in oncology

Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC).

28-03-2023

BMJ open

EffectiveNess of a multimodal preHAbilitation program in patieNts with bladder canCEr undergoing radical cystectomy: protocol of the ENHANCE multicentre randomised controlled trial.

07-03-2023

Value Health.

Cost-Effectiveness and Budget Impact of Future Developments With Whole-Genome Sequencing for Patients With Lung Cancer

26-01-2023

Key Publication

J Mol Diagn.

A Micro-Costing Framework for Circulating Tumor DNA Testing in Dutch Clinical Practice

25-01-2023

Key Publication

BMC cancer

High-dose chemotherapy with stem cell rescue to treat stage III homologous deficient breast cancer: factors influencing clinical implementation.

07-01-2023

Coverage with evidence development programs: a scoping review on characteristics and patient access.

Human epididymis protein 4 and risk of malignancy index as risk assessment tools in the decision for referral to an oncology center in patients with an ovarian mass: a cost-effectiveness analysis from a Dutch health care perspective.

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.

A comparative analysis of managed entry agreements in Europe: trends, reporting practices, and financial outcomes.

Toward a validated European instrument to measure the socioeconomic impact of cancer.

Hepatic arterial infusion pump chemotherapy combined with systemic therapy versus systemic therapy alone as induction treatment for initially unresectable colorectal liver metastases: a study protocol of the randomised controlled trial - PUMP-IT RCT.

Price transparency of cancer medicines: a crucial step towards informed pricing negotiations in the European region.

A Value-Based Evaluation Framework for Guiding the Adoption and Scale-Up of Cancer Genomics Interventions.

Hospital-based real-world evidence in health technology assessment: insights from a scoping review of European, Australian and North American guidance and expert interviews.

Budget Impact Analysis of Hyperthermic Intraperitoneal Chemotherapy With Interval Cytoreductive Surgery in Ovarian Cancer.

Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial.

Economic Evaluation of Comprehensive Genomic Profiling in an Advanced Solid Cancer Population.

Health-related quality of life of patients with metastatic melanoma treated with tumor-infiltrating lymphocytes compared with ipilimumab in a randomized phase III trial.

Socioeconomic impact among and socioeconomic support services for adolescents and young adults with cancer: A European perspective.

Cost-Effectiveness of Pembrolizumab Monotherapy for High Programmed Death Ligand 1 Advanced or Metastatic Non-small Cell Lung Cancer Depends on Long-Term Survivors.

Financial toxicity and socioeconomic impact of cancer in Europe.

Very Early Health Technology Assessment for Potential Predictive Biomarkers in the Treatment of Advanced Non-Small Cell Lung Cancer.

Early Cost-Effectiveness Analysis of Using Whole-Genome Sequencing for Patients With Castration-Resistant Prostate Cancer.

Towards Recommendations for Cost-Effectiveness Analysis of Predictive, Prognostic, and Serial Biomarker Tests in Oncology.

Defining the role of pragmatic clinical trials in cancer clinical research: outcomes of a collaborative workshop hosted by the European Organisation for Research and Treatment of Cancer.

"One more chance to survive": the experiences of patients with advanced melanoma and their partners with tumor-infiltrating lymphocyte therapy-a qualitative study and recommendations for future care.

An early economic evaluation of active surveillance for low-risk ductal carcinoma in situ.

Relevant factors for policy concerning comprehensive genomic profiling in oncology: stakeholder perspectives.

A scenario-drafting study to explore potential future implementation pathways of circulating tumor DNA testing in oncology.

DCIS knowledge of women choosing between active surveillance and surgery for low-risk DCIS.

Factors for a broad technology assessment of comprehensive genomic profiling in advanced cancer, a systematic review.

High-dose chemotherapy for patients with stage III breast cancer with homologous recombination deficiency: a discrete choice experiment among healthcare providers.

Early evaluation of the effectiveness and cost-effectiveness of ctDNA-guided selection for adjuvant chemotherapy in stage II colon cancer.

Preferences and considerations for interval cytoreductive surgery in advanced ovarian cancer: The patient's perspective.

EBCC-14 manifesto: Addressing disparities in access to innovation for patients with metastatic breast cancer across Europe.

Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.

Organization of head and neck cancer rehabilitation care: a national survey among healthcare professionals in Dutch head and neck cancer centers.

Effectiveness and Cost-Effectiveness of Survivorship Care for Survivors of Hodgkin Lymphoma (INSIGHT Study): Protocol for a Multicenter Retrospective Cohort Study With a Quasi-Experimental Design.

The socioeconomic impact of cancer on patients and their relatives: Organisation of European Cancer Institutes task force consensus recommendations on conceptual framework, taxonomy, and research directions.

Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial.

Differences in time to patient access to innovative cancer medicines in six European countries.

Early Cost-Effectiveness Analysis of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer Patients with Limited Peritoneal Carcinomatosis.

Health state utility and health-related quality of life measures in patients with advanced ovarian cancer.

Personalized surveillance and aftercare for non-metastasized breast cancer: the NABOR study protocol of a multiple interrupted time series design.

Active surveillance versus treatment in low-risk DCIS: Women's preferences in the LORD-trial.

Health-state utilities in long-term advanced melanoma survivors comparable with the general population.

Targeted combination therapies in oncology: Challenging regulatory frameworks designed for monotherapies in Europe.

Duty to recontact in genomic cancer care: A tool helping to assess the professional's responsibility.

Surveillance Imaging after Primary Diagnosis of Ductal Carcinoma in Situ.

Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC).

EffectiveNess of a multimodal preHAbilitation program in patieNts with bladder canCEr undergoing radical cystectomy: protocol of the ENHANCE multicentre randomised controlled trial.

Cost-Effectiveness and Budget Impact of Future Developments With Whole-Genome Sequencing for Patients With Lung Cancer

A Micro-Costing Framework for Circulating Tumor DNA Testing in Dutch Clinical Practice

High-dose chemotherapy with stem cell rescue to treat stage III homologous deficient breast cancer: factors influencing clinical implementation.

This site uses cookies